DK1175902T3 - Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose - Google Patents

Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose

Info

Publication number
DK1175902T3
DK1175902T3 DK01124669T DK01124669T DK1175902T3 DK 1175902 T3 DK1175902 T3 DK 1175902T3 DK 01124669 T DK01124669 T DK 01124669T DK 01124669 T DK01124669 T DK 01124669T DK 1175902 T3 DK1175902 T3 DK 1175902T3
Authority
DK
Denmark
Prior art keywords
arteriosclerosis
medicament
treatment
olmesartan
manufacture
Prior art date
Application number
DK01124669T
Other languages
Danish (da)
English (en)
Inventor
Yoshio Tsujita
Toshihiko Fujiwara
Toshio Sada
Naoyuki Maeda
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of DK1175902T3 publication Critical patent/DK1175902T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01124669T 1996-07-15 1997-07-11 Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose DK1175902T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18436896 1996-07-15

Publications (1)

Publication Number Publication Date
DK1175902T3 true DK1175902T3 (da) 2005-12-19

Family

ID=16152008

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01124669T DK1175902T3 (da) 1996-07-15 1997-07-11 Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose
DK97930762T DK0930076T3 (da) 1996-07-15 1997-07-11 Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97930762T DK0930076T3 (da) 1996-07-15 1997-07-11 Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom

Country Status (18)

Country Link
US (1) US6610682B2 (cs)
EP (2) EP1175902B1 (cs)
KR (1) KR100540618B1 (cs)
CN (2) CN1221259C (cs)
AT (2) ATE283704T1 (cs)
AU (1) AU714618B2 (cs)
CA (1) CA2261040C (cs)
CZ (2) CZ300089B6 (cs)
DE (2) DE69731840T2 (cs)
DK (2) DK1175902T3 (cs)
ES (2) ES2232873T3 (cs)
HU (2) HU225415B1 (cs)
IL (2) IL128059A (cs)
NO (2) NO322314B1 (cs)
NZ (1) NZ333723A (cs)
PT (1) PT930076E (cs)
RU (2) RU2220723C2 (cs)
WO (1) WO1998002183A1 (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
PE20020229A1 (es) * 2000-04-12 2002-04-11 Novartis Ag COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
HRP20050754A2 (en) * 2003-01-31 2005-10-31 Sankyo Company Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
JP5148296B2 (ja) * 2005-06-27 2013-02-20 第一三共株式会社 アンジオテンシンｉｉ受容体拮抗剤及びカルシウム拮抗剤含有医薬組成物
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
MY145616A (en) 2005-10-04 2012-03-15 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20090076104A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched losartan
BRPI0922043B1 (pt) * 2008-11-19 2019-04-24 Merial, Inc. Composições compreendendo um aril pirazol e/ou formamidina, métodos e usos das mesmas
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107617107A (zh) * 2017-09-18 2018-01-23 浙江大学 一种复方血管紧张素转换酶类抗瘢痕制剂
CN107648611A (zh) * 2017-09-18 2018-02-02 浙江大学 复方血管紧张素转换酶类抗瘢痕外用制剂
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
US5231080A (en) 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3925759A1 (de) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2229000C (en) * 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1994001433A1 (fr) * 1992-07-13 1994-01-20 Japan Tobacco Inc. Nouveau compose de thiazolidinedione et son utilisation
AU6114794A (en) * 1993-02-24 1994-09-14 Sankyo Company Limited Arteriosclerosis remedy
JPH0741423A (ja) 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
DE4318813A1 (de) * 1993-06-07 1994-12-08 Merck Patent Gmbh Imidazopyridine
CA2145257A1 (en) * 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CA2650637A1 (en) 1996-04-05 1997-10-16 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing angiotensin ii antagonist

Also Published As

Publication number Publication date
DE69734405D1 (de) 2006-03-02
CN1221259C (zh) 2005-10-05
AU3459597A (en) 1998-02-09
HUP9903166A2 (hu) 2000-09-28
DE69731840D1 (de) 2005-01-05
NO20056021L (no) 1999-03-15
CZ10299A3 (cs) 1999-06-16
CZ299162B6 (cs) 2008-05-07
KR20000023757A (ko) 2000-04-25
EP1175902A1 (en) 2002-01-30
CN1230122A (zh) 1999-09-29
IL128059A (en) 2003-12-10
HUP9903166A3 (en) 2003-09-29
HUP0600501A3 (en) 2008-10-28
CN1476833A (zh) 2004-02-25
PT930076E (pt) 2005-01-31
KR100540618B1 (ko) 2006-01-12
HK1020260A1 (en) 2000-04-07
US20020013308A1 (en) 2002-01-31
HU0600501D0 (en) 2006-08-28
NO322314B1 (no) 2006-09-11
HU227399B1 (en) 2011-05-30
ES2232873T3 (es) 2005-06-01
EP0930076A1 (en) 1999-07-21
CA2261040C (en) 2009-01-20
WO1998002183A1 (fr) 1998-01-22
NZ333723A (en) 2000-09-29
CA2261040A1 (en) 1998-01-22
ATE283704T1 (de) 2004-12-15
CZ300089B6 (cs) 2009-01-28
DK0930076T3 (da) 2005-01-31
EP1175902B1 (en) 2005-10-19
IL145758A (en) 2006-06-11
DE69731840T2 (de) 2005-08-04
HU225415B1 (en) 2006-11-28
NO990166L (no) 1999-03-15
EP0930076B1 (en) 2004-12-01
EP0930076A4 (en) 2001-10-04
NO334217B1 (no) 2014-01-13
CN1155409C (zh) 2004-06-30
ATE306921T1 (de) 2005-11-15
RU2220723C2 (ru) 2004-01-10
US6610682B2 (en) 2003-08-26
RU2183128C2 (ru) 2002-06-10
DE69734405T2 (de) 2006-08-03
IL128059A0 (en) 1999-11-30
AU714618B2 (en) 2000-01-06
NO990166D0 (no) 1999-01-14
ES2250283T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
DK1175902T3 (da) Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose
SE9604786D0 (sv) New compounds
FR11C0038I2 (fr) Analogues macrocycliques, leurs procedes d'utilisation et de preparation
MX9804597A (es) Derivados de bencimidazol sustituidos por naftilo como anticoagulantes.
ATE190834T1 (de) Orale zusammensetzung gegen zahnbelag
HUP9800806A2 (hu) Abszorbens cikkek folyadék kezelésére
NO975716D0 (no) Imidazolforbindelser
RU2001126527A (ru) Средство и способ лечения или профилактики артериосклероза
ATE369827T1 (de) Wegwerfwindel
BRPI0602329A (pt) composição de cuidados orais, dispositivos e métodos de uso das mesmas
FI971523A0 (fi) Bentsopyraani- ja bentsofuusioituja yhdisteitä, niiden valmistus ja käyttö leukotrieeni B4':n (LTB4) antagonisteina
ATE219073T1 (de) Benzopyran derivate mit leukotrien- antagonistischer wirkung
ES556864A0 (es) Procedimiento para la obtencion de benzopiranos sustituidos.
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
ES2091261T3 (es) Utilizacion de un agente microbicida en la fabricacion de tejas de hormigon.
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
SE9504662D0 (sv) New compounds
EP0338415A3 (en) Use of sulphonylureas in the treatment of oedema
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
TR200000154T2 (tr) 2,4,4-Trisübstitüe-1,3-Dioksolan mantar önleyiciler.
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
ATE325637T1 (de) Arzneimittelzubereitung mit antiarteriosklerotischer wirkung
TR199701286T1 (xx) Karbapenemlerin esterleri.